Therapies for depression in Parkinson's disease (Q24248733)

Europe PubMed Central

title

Therapies for depression in Parkinson's disease (English)

0 references

1 reference

3

0 references

author name string

Shabnam Ghazi-Noori

1

0 references

Tin Hei Chung

2

0 references

Hugh E Rickards

4

0 references

Carl E Clarke

Cochrane Database of Systematic Reviews

5

0 references

publication date

22 April 2003

0 references

published in

0 references

cites work

Nomifensine in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

Treatment of depression in Parkinson's disease with moclobemide: A pilot open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

Bupropion in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

Sertraline for the treatment of depression in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

Selegiline and cognitive function in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

Amitriptyline in the treatment of headache in patients with Parkinson's disease: a double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

Deprenyl in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

Improvement in Parkinsonian symptoms after repetitive transcranial magnetic stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

Nomifensine in parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

Electroconvulsive therapy in Parkinson's disease: 30 month follow up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

Electroconvulsive therapy for the physical signs of Parkinson's disease without depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

The Therapeutic Potential of Moclobemide, a Reversible Selective Monoamine Oxidase A Inhibitor in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

Moclobemide and selegeline in the treatment of depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

Depression and Parkinson's disease: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

Treatment of depression in Parkinson's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

What contributes to quality of life in patients with Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

Tolerability of paroxetine in Parkinson's disease: A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

7 January 2021

Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

7 January 2021

Short-term effects of behavioral treatment on movement initiation and postural control in Parkinson's disease: A controlled clinical study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

7 January 2021

Therapeutic and “dose-dependent” effect of repetitive microelectroshock induced by transcranial magnetic stimulation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

7 January 2021

Electroconvulsive Therapy in the Treatment of Combined Depression and Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

7 January 2021

NORTRIPTYLINE FOR THE TREATMENT OF DEPRESSION IN PROGRESSIVE SUPRANUCLEAR PALSY

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

7 January 2021

Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

7 January 2021

IMIPRAMINE IN TREATMENT OF PARKINSONISM: A DOUBLE-BLIND PLACEBO STUDY

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

7 January 2021

Parkinsonism exacerbated by paroxetine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

7 January 2021

Paroxetine in Parkinson's disease: effects on motor and depressive symptoms

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003465

7 January 2021